Athera

Athera Biotechnologies is a clinical-stage biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs for the prevention and treatment of cardiovascular disease. It develops ATH3G10, a human monoclonal antibody binding to oxidized phospholipid, that acts to support the immune response to vascular inflammation.